Synapsin-3: A Protein Target for Neurological Disorders (G8224)

Target Name: SYN3

NCBI ID: G8224

SYN3

Synapsin-3: A Protein Target for Neurological Disorders

Synapsin-3 (ISOform IIIg) is a protein that is expressed in the nervous system and has been shown to play a role in the transmission of neural signals. Mutations in the Synapsin-3 gene have been linked to a variety of neurological and psychiatric disorders , including Alzheimer's disease, Parkinson's disease, and schizophrenia. As a result, Synapsin-3 has become a promising drug target for researchers.

Synapsin-3 is a transmembrane protein that is composed of four subunits. It is expressed in the brain and plays a critical role in the transmission of neural signals from the sensory cortices to the motor cortices. Synapsin-3 is composed of two transmembrane domains, a N-terminus domain, and a C-terminus domain. The N-terminus domain is responsible for the protein's ability to interact with intracellular signaling molecules, while the C-terminus domain is responsible for the protein's ability to interact with other proteins.

Synapsin-3 has been shown to play a role in a variety of neural processes, including the transmission of sensory information, the regulation of neurotransmitter release, and the modulation of neural activity. One of the most interesting functions of Synapsin-3 is its role in the regulation of synaptic transmission. Synapsin-3 plays a crucial role in transmitting information between neurons.

Mutations in Synapsin-3 can lead to neuronal apoptosis, damage synaptic structure, and then lead to impaired neurotransmission function. In addition, Synapsin-3 is also related to neuronal apoptosis. Apoptosis is an important neurobiological process and is of great significance for neuronal damage and treatment.

Synapsin-3 is considered a potential drug target due to its important role in neurotransmission. Researchers are exploring the use of small molecules, antibodies, and other biochemical approaches to target Synapsin-3 and its associated signaling pathways in order to treat a variety of neurological and psychiatric disorders.

In addition to its potential therapeutic applications, Synapsin-3 also has significant potential as a biomarker for the diagnosis and monitoring of neurological disorders. The loss of Synapsin-3 has been observed in a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, the level of Synapsin-3 expression in a patient's brain or urine can be a valuable diagnostic or monitoring tool for these disorders.

In conclusion, Synapsin-3 is a protein that plays a critical role in the transmission of neural signals in the nervous system. Its mutations have been linked to a variety of neurological and psychiatric disorders, making it an attractive drug target for researchers. Additionally, Synapsin-3 has significant potential as a biomarker for the diagnosis and monitoring of these disorders. Further research is needed to fully understand the role of Synapsin-3 in neural processes and its potential as a therapeutic agent.

Protein Name: Synapsin III

Functions: May be involved in the regulation of neurotransmitter release and synaptogenesis

The "SYN3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SYN3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets